Precision ONCOLOGY Explained
Precision oncology Explained
The completion of the Human Genome Project in 2003 made possible a new era of faster, more affordable, and more accurate genome analysis of cancers that is now referred to as Next Generation Sequencing (NGS). By looking at tumor DNA using NGS, doctors and researchers were able to better understand the genetic causes of cancers and began to unravel which treatments or prevention strategies might work in which patients. It became clear that cancers have different and unique underlying genetic causes and these genetic causes could be exploited to better individualize and target therapies.
Levels of Precision
At Perthera, precision Oncology is only the first component of your personalized cancer journey. While the precision begins with targeted therpay options, we maintain that same individual focus each step of the way:
- A Perthera Coordinator is assigned to every patient to guide them through Perthera’s process
- Medical and treatment history is obtained for every patient
- Every patient’s case is reviewed by Perthera’s expert medical and scientific tumor board
- Every patient who consents is followed and outcomes are made a part of Perthera’s Therapeutic Intelligence Engine.
Next-Generation Sequencing (NGS)
DNA or RNA analysis that examines genes for mutations and other genomic changes present in a cancer cell. This testing usually requires a solid tissue sample.
Liquid Biopsy Testing: A test done on a sample of blood to look for cancer cells from a tumor that are circulating in the blood or pieces of free-floating DNA. Liquid biopsy can only detect a fraction of the genes that NGS can detect, but is much faster and can provide important data on known mutated genes of interest.
Perthera uses comprehensive molecular testing to identify actionable changes in a cancer cell’s genome.